Winners of the 2019 European PRRS Research Award announced

Ingelheim, Germany, Mon, 10/07/2019 - 09:00

Boehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro each.
The company sponsored the annual European PRRS Awards for the sixth time.

Ingelheim, Germany, 7 October 2019 – Boehringer Ingelheim honors three winning research proposals with a funding of 25,000 euro each as part of the European PRRS Awards to encourage further development of practical methods for controlling PRRS (Porcine Reproductive and Respiratory Syndrome), and to recognize scientific excellence in this field. Furthermore, the company offers a valuable opportunity for interaction and academic exchange among swine researchers and veterinary practitioners. The winners were selected by an independent expert panel.

PRRS continues to be a highly prevalent disease¹ in European pigs, causing economic losses² through its negative effects on reproduction and growth as well as by clinical illness.

The European PRRS Research Award review board is chaired by Enric Mateu (Universidad Autònoma de Barcelona) with members from across swine practice and academia: Helle Jessen (Hyo Vet), Andrea Ladinig (Vetmeduni Vienna), Giampietro Sandri (Gruppo Veronesi), Gyula Balka (Veterinary Medicine Budapest) ), Michele Drigo (University of Padova), adnd Torsten Pabst (Tierarztpraxis Dr. Pabst).

In 2019, the company has sponsored the annual European PRRS Research Award for the sixth time already. The winners of this year’s European PRRS Research Award, as selected by the review board after careful evaluation, are:

Role of cytotoxic T lymphocytes in gilts after MLV vaccination in protection against vertical transmission of PRRSV (Yanli Li, Universitat Autònoma de Barcelona – Spain)
Impact of repeated vaccinations with MLV PRRSV vaccines on the adaptive immune response (Lars Erik Larsen, University of Copenhagen – Denmark)
Molecular traceability of PRRSV: an epidemiological tool for improving biosecurity (Gerard Eduard Martín Valls, Universitat Autònoma de Barcelona – Spain)

The prizes will be awarded to the winners at the 12^th European Symposium of Porcine Health Management in 2020 taking place in Bern, Switzerland.

For further information please visit: www.prrs.com.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.